Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,136.14
(
1.35%
)
US TECH 100
25,958.40
(
1.33%
)
Dow Jones
49,598.23
(
2.19%
)
Brent Oil
88.29
(
-7.08%
)
Bitcoin
77,288.03
(
2.80%
)
News Focus
News Focus
Post# of 15767
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

J-RO

Send PM Follow Ignore
Followers 160
Posts 21546
Boards Moderated 1
Alias Born 06/28/2006

J-RO

Re: lidopete post# 704

Monday, 09/10/2007 10:03:07 AM

Monday, September 10, 2007 10:03:07 AM

Post# of 15767
IN PLAY Feature =>
6:05AM ADVENTRX Pharma announces ANX-514 clinical development plan affirmed by FDA (ANX) 2.32 : Co announces that it has received confirmation from the FDA regarding its proposed 505(b)(2) NewDrug Application regulatory path for ANX-514. The FDA has indicated that data from a single study of approx 28 patients that demonstrates the bioequivalence of ANX-514 and docetaxel is sufficient tosupport filing an NDA.

http://finance.yahoo.com/marketupdate/inplay

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today